LEGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Legend Biotech Corp
Financials through Q4 FY2025, quarter ended Dec 31, 2025Last filing: 20-F on Mar 10, 2026
$18.65+0.17 (+0.92%)
Close on Oct 19, 2026
- Market cap
- $6.89B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2017 to 2025
Gross margin
61.4%−38.6 pts over 5 years
Operating margin
-13.3%
Net margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +64.0% | +106.4% | +68.8% | – | |
| Gross profit | +53.8% | +130.4% | +53.1% | – |
Returns and balance sheet
9 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -71.1% | – | |
| Return on assets | – | -52.5% | – | |
| Current ratio | – | 5.14 | 1.96 | |
| Debt to equity | – | – | – | |
| Interest coverage | – | – | -6.4× | |
| Inventory turnover | – | 0.0× | 14.2× | |
| Capex to revenue | – | 35.0% | 2.8% | |
| Diluted shares | – | 236M | 369M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Legend Biotech generated $1.04B from operations and spent $125.92M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$1.04B
Used
$125.92M
Capital expenditure$125.92M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-28.2%
×Asset turnover0.36×
×Equity multiplier1.54×
=Return on equity, FY2024-15.4%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2024 | -28.2% | 0.36× | 1.54× | -15.4% |
| FY2023 | -181.8% | 0.18× | 1.59× | -51.9% |
| FY2022 | -381.5% | 0.10× | 1.62× | -59.1% |
| FY2021 | -586.4% | 0.07× | 1.35× | -59.2% |
| FY2020 | -355.2% | 0.15× | 1.35× | -71.1% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero–
- Cash generatingOperating cash flow above zero-$100.20M
- Return on assets improvedROA up on the prior year-9.6% → –
- Earnings backed by cashOperating cash flow above net income-$100.20M vs –
- Less leverageLong-term debt to assets fell18.0% → 0.0%
- Better liquidityCurrent ratio rose4.62 → 1.96
- No dilutionShare count did not rise366M → 369M
- Gross margin improvedGross margin up on the prior year65.50% → 61.41%
- More efficientAsset turnover rose0.34 → 0.62